Royal Victoria Eye & Ear Hospital Research Foundation : Frontiers in Ophthalmology 2017 : Professor John Crown

Royal Victoria Eye & Ear Hospital Research Foundation
New Frontiers in Ophthalmology

Dublin, Ireland / June 15th 2017 / Chair Mr. Noel Horgan

'Drug Therapy of Ocular Melanoma'
Professor John Crown,
Consultant Medical Oncologist,
St Vincents University Hospital, Dublin

01. Drug Therapy of Ocular Melanoma

02. Chemotherapy

03. Drug therapy metastatic melanoma

04. Adjuvant Fotemustine versus surveillance in high-risk uveal melanoma ASCO 2017

05. Intra-hepatic chemosaturation

06. Intra-hepatic chemosaturation – Phase III data

07. Immunotherapy

08. Early Immune Therapy 1960-1990s

09. Checkpoint Inhibitors

10. Biologic Rationale for Combined PD-1 and CTLA-4 Blockade

11. Overall Survival

12. CTLA-4 Immune Checkpoint Pathway Inhibition

13. Overall Survival for Patients with Melanoma Treated with Nivolumab

14. Overall Survival

15. Incidence of Immune-Mediated AEs

16. CheckMate 069 Trial

17. Tumor Burden Change from Baseline

18. Immunotheraphy & UM

19. Treatment Responses

20. Best Overall Response

21. Survival Estimates

22. UM; Immunotheraphy-Resistant

23. Combination IpiIimumab/Nivolumuab

24. MAPK Pathway; Ras/Raf/MEK/ERK Signal Transduction

25. BRIM-3 Progression

26. Graph

27. Image

28. STREAM; Sorafenib in MUM

29. METRIC Overall Survival – ITT

30. Targeting the MAPK kinase pathway (II)

31. Selumetinib

32. COMDI-d Randomized, double-blinded Phase III

33. Study Rationale

34. COMBI-d: Overall Survival

35. Image

36. Current Problems

37. Question/Answer 01

38. Question/Answer 02